Company Overview of Novartis Pharma AG
Novartis Pharma AG provides treatments for Alzheimer’s disease, Parkinson’s disease, Attention-Deficit/Hyperactivity Disorder, epilepsy, schizophrenia, and migraine. It is also developing a treatment for type 2 diabetes; drugs therapies that improve insulin action to increase glucose disposal in the muscle, to limit its production in the liver, and to improve the kinetics of insulin secretion; and oral and physiological approach to enhancing glucagon like peptide-1 activity, which acts to stimulate insulin secretion and inhibit glucagon production. The company is based in Basel, Switzerland. Novartis Pharma AG operates as a subsidiary of Novartis AG.
41 61 324 11 11
41 61 324 80 01
Key Executives for Novartis Pharma AG
Novartis Pharma AG Key Developments
Similar Private Companies By Industry
|ErgoNex Pharma GmbH||Europe|
|Dompé International SA||Europe|
Recent Private Companies Transactions
August 21, 2015
|GlaxoSmithKline plc, Remaining Rights to Ofatumumab|
January 23, 2015
|Novartis Pharma AG, Worldwide Rights to encorafenib (LGX-818)|
To contact Novartis Pharma AG, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.